Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Convertible Debt Curent Deferred Tax Liability Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Leases Current Taxes Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares

Daily Values

Growth Metrics

Others

Ligand Pharmaceuticals (LGND) Work In Process (2023 - 2024)

Historic Work In Process for Ligand Pharmaceuticals (LGND) over the last 2 years, with Q4 2024 value amounting to $3.9 million.

Ligand Pharmaceuticals' Work In Process rose 191179.49% to $3.9 million in Q4 2024 from the same period last year, while for Dec 2024 it was $3.9 million, marking a year-over-year increase of 191179.49%. This contributed to the annual value of $3.9 million for FY2024, which is 191179.49% up from last year.
Ligand Pharmaceuticals' Work In Process amounted to $3.9 million in Q4 2024, which was up 191179.49% from $260000.0 recorded in Q3 2024.
Ligand Pharmaceuticals' Work In Process' 5-year high stood at $3.9 million during Q4 2024, with a 5-year trough of $195000.0 in Q4 2023.